Global Denosumab Market Report 2024

Denosumab Global Market Report 2024 – By Drug Classification (Prolia, Xgeva, Others), By Type (60 mg, 120 mg), By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2024-2033

Denosumab Global Market Report 2024

Starting Price : $5000.00 | Pages : 175 | Published : March 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Denosumab Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Denosumab Market Definition And Segments

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture.

The main types of denosumab drug classifications include Prolia, Xgeva, and others. Prolia refers to a prescription medicine utilized to treat osteoporosis in postmenopausal women who are at high risk for fracture or cannot use another osteoporosis medication. These are available in 60 mg and 120 mg, which are used by various end-users, such as hospitals, home care, specialty clinics, and ambulatory surgical centers.

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

The denosumab market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to clinical trials and research advancements, FDA approvals and regulatory milestones, growing awareness of bone health, strategic partnerships and marketing initiatives.

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising incidence of bone metastases, advancements in cancer therapies, osteoporosis prevalence, increased awareness of osteoporosis, regulatory approvals for new indications. Major trends in the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, advancements in biosimilar development.

Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence

The increasing prevalence of osteoporosis is expected to propel the growth of the denosumab market going forward. Osteoporosis is a medical condition where the bones become weak, resulting in lower bone density and a higher risk of fractures. Denosumab is used to treat osteoporosis by stopping bone resorption through the targeting of the RANK ligand. For instance, In December 2023, according to a report published by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, osteoporosis contributed to 2,366 deaths, or 6.5 deaths per 100,000 population in 2021, representing 1.4% of all deaths. Further, in 2021–22, there were 9,500 hospitalizations with a principal diagnosis of osteoporosis (89 hospitalizations per 100,000 population) for people aged 45 and over. Therefore, the increasing prevalence of osteoporosis is driving the growth of the denosumab market.

Major companies operating in the denosumab market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

Emphasis On First-Line Denosumab Treatments For Osteoporosis

Major companies operating in the denosumab market are increasing their focus on introducing innovative solutions, such as first-line treatments for osteoporosis, to gain a competitive edge in the market. First-line treatment for osteoporosis refers to the initial or primary therapeutic approach recommended by healthcare professionals when managing individuals diagnosed with osteoporosis. For instance, in November 2022, Boan Biotech, a China-based biotechnology company, received approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, making it the first Chinese company to develop a denosumab injection. It is also being developed for markets outside of China, including Europe and the United States, with plans for global marketing. The drug has been recommended as a first-line treatment for osteoporosis in various treatment guidelines. The medication has the potential to dramatically lower the risk of hip, non-vertebral, and vertebral fractures in this patient population. Additionally, Boyoubei is the first biosimilar to Prolia (the originator of denosumab) approved for marketing in the world.

Organon Partners With Henlius To Commercialize Investigational Biosimilars

In June 2022, Organon, a US-based pharmaceutical company, partnered with Henlius to commercialize Henlius for an undisclosed amount. The partnership allows Organon to license the commercialization rights for biosimilar candidates referencing Perjeta (Pertuzumab, HLX11) and Prolia or Xgeva (Denosumab). This collaboration is in line with Organon's expertise in biosimilar commercialization and its commitment to offering high-quality and affordable biologic medicines for patients worldwide, particularly in the field of women's health. Henlius is a China-based biopharmaceutical company that develops Denosumab biosimilars, such as HLX14

North America was the largest region in the denosumab market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the denosumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The denosumab market research report is one of a series of new reports from The Business Research Company that provides denosumab market statistics, including denosumab industry global market size, regional shares, competitors with a denosumab market share, detailed denosumab market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. This denosumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Denosumab Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $3.27 billion
Revenue Forecast In 2033 $5.06 billion
Growth Rate CAGR of 11.5% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Novartis International AG; Sanofi SA; GlaxoSmithKline plc; Eli Lilly and Company; Amgen Inc.; Asahi Kasei Corporation; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Company, Limited; Mylan N.V.; Sandoz International GmbH; Daiichi Sankyo Company Limited; Aurobindo Pharma Limited; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Hikma Pharmaceuticals PLC; Celltrion Inc.; Amneal Pharmaceuticals Inc; Cadila Healthcare Limited; Lupin Limited; Biocon Limited; Torrent Pharmaceuticals Ltd.; Jubilant Life Sciences Limited; Ajanta Pharma Limited
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Denosumab Market Characteristics

    3. Denosumab Market Trends And Strategies

    4. Denosumab Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Denosumab Market Size and Growth

    5.1. Global Denosumab Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Denosumab Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Denosumab Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Denosumab Market Segmentation

    6.1. Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Prolia

    Xgeva

    Others

    6.2. Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    60 mg

    120 mg

    6.3. Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Homecare

    Specialty Clinics

    Ambulatory Surgical Centers

    7. Denosumab Market Regional And Country Analysis

    7.1. Global Denosumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Denosumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Denosumab Market

    8.1. Asia-Pacific Denosumab Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Denosumab Market

    9.1. China Denosumab Market Overview

    9.2. China Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Denosumab Market

    10.1. India Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Denosumab Market

    11.1. Japan Denosumab Market Overview

    11.2. Japan Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Denosumab Market

    12.1. Australia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Denosumab Market

    13.1. Indonesia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Denosumab Market

    14.1. South Korea Denosumab Market Overview

    14.2. South Korea Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Denosumab Market

    15.1. Western Europe Denosumab Market Overview

    15.2. Western Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Denosumab Market

    16.1. UK Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Denosumab Market

    17.1. Germany Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Denosumab Market

    18.1. France Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Denosumab Market

    19.1. Italy Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Denosumab Market

    20.1. Spain Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Denosumab Market

    21.1. Eastern Europe Denosumab Market Overview

    21.2. Eastern Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Denosumab Market

    22.1. Russia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Denosumab Market

    23.1. North America Denosumab Market Overview

    23.2. North America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Denosumab Market

    24.1. USA Denosumab Market Overview

    24.2. USA Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Denosumab Market

    25.1. Canada Denosumab Market Overview

    25.2. Canada Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Denosumab Market

    26.1. South America Denosumab Market Overview

    26.2. South America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Denosumab Market

    27.1. Brazil Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Denosumab Market

    28.1. Middle East Denosumab Market Overview

    28.2. Middle East Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Denosumab Market

    29.1. Africa Denosumab Market Overview

    29.2. Africa Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Denosumab Market Competitive Landscape And Company Profiles

    30.1. Denosumab Market Competitive Landscape

    30.2. Denosumab Market Company Profiles

    30.2.1. Johnson & Johnson

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. F. Hoffmann-La Roche Ltd.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Novartis International AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Sanofi SA

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. GlaxoSmithKline plc

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Denosumab Market Other Major And Innovative Companies

    31.1. Eli Lilly and Company

    31.2. Amgen Inc.

    31.3. Asahi Kasei Corporation

    31.4. Teva Pharmaceutical Industries Ltd.

    31.5. Astellas Pharma Inc.

    31.6. Daiichi Sankyo Company, Limited

    31.7. Mylan N.V.

    31.8. Sandoz International GmbH

    31.9. Daiichi Sankyo Company Limited

    31.10. Aurobindo Pharma Limited

    31.11. Cipla Limited

    31.12. Dr. Reddy's Laboratories Ltd.

    31.13. Hikma Pharmaceuticals PLC

    31.14. Celltrion Inc.

    31.15. Amneal Pharmaceuticals Inc

    32. Global Denosumab Market Competitive Benchmarking

    33. Global Denosumab Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Denosumab Market

    35. Denosumab Market Future Outlook and Potential Analysis

    35.1 Denosumab Market In 2028 - Countries Offering Most New Opportunities

    35.2 Denosumab Market In 2028 - Segments Offering Most New Opportunities

    35.3 Denosumab Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Denosumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Denosumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Johnson & Johnson Financial Performance
  • Table 75: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 76: Novartis International AG Financial Performance
  • Table 77: Sanofi SA Financial Performance
  • Table 78: GlaxoSmithKline plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Denosumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Denosumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Johnson & Johnson Financial Performance
  • Figure 75: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 76: Novartis International AG Financial Performance
  • Figure 77: Sanofi SA Financial Performance
  • Figure 78: GlaxoSmithKline plc Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the denosumab market?

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture. For further insights on the denosumab market, request a sample here

How will the denosumab market drivers and restraints affect the denosumab market dynamics? What forces will shape the denosumab industry going forward?

The denosumab market major growth driver - Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence. For further insights on the denosumab market, request a sample here

What is the forecast market size or the forecast market value of the denosumab market?

The denosumab market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to clinical trials and research advancements, FDA approvals and regulatory milestones, growing awareness of bone health, strategic partnerships and marketing initiatives. The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising incidence of bone metastases, advancements in cancer therapies, osteoporosis prevalence, increased awareness of osteoporosis, regulatory approvals for new indications. Major trends in the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, advancements in biosimilar development. For further insights on the denosumab market, request a sample here

How is the denosumab market segmented?

The denosumab market is segmented
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical CentersFor further insights on the denosumab market,
request a sample here

Which region has the largest share of the denosumab market? What are the other regions covered in the report?

North America was the largest region in the denosumab market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the denosumab market, request a sample here.

Who are the major players in the denosumab market?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited For further insights on the denosumab market, request a sample here.

What are the key trends in the denosumab market?

Major trend in the denosumab market - Emphasis On First-Line Denosumab Treatments For Osteoporosis. For further insights on the denosumab market, request a sample here.

What are the major opportunities in the denosumab market? What are the strategies for the denosumab market?

For detailed insights on the major opportunities and strategies in the denosumab market, request a sample here.

How does the denosumab market relate to the overall economy and other similar markets?

For detailed insights on denosumab market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the denosumab industry?

For detailed insights on the mergers and acquisitions in the denosumab industry, request a sample here.

What are the key dynamics influencing the denosumab market growth? SWOT analysis of the denosumab market.

For detailed insights on the key dynamics influencing the denosumab market growth and SWOT analysis of the denosumab industry, request a sample here.